Lorukafusp alfa clinical trials
Also written hu14.18-IL2.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses lorukafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
University of Wisconsin, Madison (3) · Children's Oncology Group (2)
Studies
Open first, then newest update. How each study uses lorukafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedPhase 1/2University of Wisconsin, MadisonNCT03958383Written as hu14.18-IL2How we know
- Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2WithdrawnPhase 1University of Wisconsin, MadisonNCT03209869Written as Hu14.18-IL2How we know
- Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV MelanomaCompletedPhase 2University of Wisconsin, MadisonNCT00590824Written as hu14.18-IL2How we know
- Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory NeuroblastomaCompletedPhase 2Children's Oncology GroupNCT01334515Written as hu14.18-IL2 fusion proteinHow we know
- hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory NeuroblastomaCompletedPhase 2Children's Oncology GroupNCT00082758Written as hu14.18-Interleukin-2 fusion proteinHow we know
Codes
What other systems call lorukafusp alfa · ClinicalTrials.gg INT004716
- MeSH (NLM) C493743lorukafusp alfaOne source NLM
- UNII (FDA) PL21OR4LXELORUKAFUSP ALFAConfirmed FDA, NLM
- NCI Thesaurus C162537Lorukafusp alfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C493743 | lorukafusp alfa | One source NLM |
| UNII (FDA) | PL21OR4LXE | LORUKAFUSP ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C162537 | Lorukafusp alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.